Home›Urology› Multi-protein panels improve gastric cancer diagnosis over single markers
Multi-protein panels improve gastric cancer diagnosis over single markersProtein Microarrays Show Better Diagnostic Performance for Gastric Cancer
Frontiers in MedicinePublished September 5, 2026Study authors: Panning Wang, Yu-Lin Xiao, Shuhong Luo, Hua Dong, Ruo-Pan HuangDOI ↗Editorial oversight: Dr. Lars van Dijk, PhD · Surgical, Procedural & Diagnostic
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider multi-protein panels as a promising diagnostic tool, but await validation in clinical trials.
This systematic review evaluates the role of protein microarray-based proteomics in gastric cancer. The scope includes biomarker discovery, molecular subtyping, characterization of the tumor microenvironment, and assessment of therapeutic response. The review synthesizes evidence from studies using protein microarray technology, comparing multi-protein panels with conventional single-marker assays.
Key findings indicate that multi-protein biomarker panels, especially when integrated with computational approaches, demonstrate improved diagnostic performance compared with conventional single-marker assays. This suggests that a panel-based approach may offer greater accuracy in detecting gastric cancer. The review also highlights the potential of proteomics for molecular subtyping and understanding the tumor microenvironment, which could inform treatment strategies.
However, the review does not report specific effect sizes, sample sizes, or patient populations. The authors note that while there is potential for clinical translation, specific clinical trial data are not provided. Limitations of the included studies are not reported, and the certainty of evidence is not graded.
For clinicians, this review underscores the promise of proteomic panels in improving gastric cancer diagnosis, but it is not yet ready for direct clinical application. Further validation in prospective trials is needed before these findings can influence practice.
How this fits prior evidence
This systematic review extends prior coverage by focusing on protein-based biomarkers for diagnosis, whereas earlier items addressed treatment selection and response prediction. It confirms the trend toward multi-marker and computational approaches, aligning with the finding that AI models outperform traditional assessment in predicting neoadjuvant chemotherapy response. It also complements biomarker-guided therapy by suggesting that proteomic panels could improve diagnostic accuracy, though it does not address surgical outcomes or therapeutic efficacy directly.
Researchers reviewed the use of protein microarray-based proteomics to help identify and understand gastric cancer. This technology looks at many different proteins at once instead of looking at just one marker at a time. The review compared these multi-protein panels to conventional single-marker assays.
The findings show that using multiple protein panels combined with computer analysis can improve diagnostic performance. These methods also help researchers better understand the tumor microenvironment and identify different types of cancer. This approach may help doctors see a more complete picture of the disease.
While these results are promising for the future of cancer testing, it is important to note that this was a review of existing research. The study did not provide specific clinical trial data or information on how these tests perform in a standard doctor's office. These findings are currently used for research and biomarker discovery rather than immediate changes in patient care.
What this means for you:
Multi-protein panels may improve gastric cancer diagnosis compared to traditional single-marker tests.
Common questions
How is this different from current tests?
Current tests often use a single marker to identify a condition. This research looks at multi-protein biomarker panels. By looking at many proteins at once and using computer analysis, these panels may provide better diagnostic performance than the standard single-marker assays.
Can this method help identify different types of cancer?
Yes, the use of protein microarray-based proteomics can help with molecular subtyping. This means it can help researchers better understand the specific characteristics of the tumor microenvironment and identify different types of gastric cancer.
Gastric cancer remains a major cause of cancer-related mortality worldwide, largely due to late diagnosis and pronounced molecular heterogeneity. Although genomic and transcriptomic studies have advanced understanding of gastric tumor biology, they do not fully capture dynamic changes in protein expression, post-translational modifications, and signaling activity that directly regulate cellular function. High-throughput proteomic technologies, particularly protein microarrays, have emerged as powerful platforms for systematic protein profiling in complex biological samples. These technologies enable the simultaneous quantification of hundreds to thousands of proteins with high sensitivity and minimal sample requirements, supporting both discovery and translational research. Recent applications of protein microarrays in gastric cancer include biomarker discovery for early diagnosis, molecular subtyping, characterization of the tumor microenvironment, and assessment of therapeutic response. Multi-protein biomarker panels and integration with computational approaches have demonstrated improved diagnostic performance compared with conventional single-marker assays. In addition, proteomic profiling has provided insights into key signaling pathways and immune-related mechanisms underlying tumor progression and drug resistance. This review summarizes the principles and major formats of protein microarray technologies and highlights their applications in gastric cancer. Current challenges and future directions for clinical translation are also discussed.
